Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Operating Margin (2016 - 2025)

Vanda Pharmaceuticals' Operating Margin history spans 16 years, with the latest figure at 70.53% for Q4 2025.

  • For Q4 2025, Operating Margin fell 5120.0% year-over-year to 70.53%; the TTM value through Dec 2025 reached 69.95%, down 4950.0%, while the annual FY2025 figure was 69.95%, 4950.0% down from the prior year.
  • Operating Margin for Q4 2025 was 70.53% at Vanda Pharmaceuticals, down from 55.61% in the prior quarter.
  • Across five years, Operating Margin topped out at 18.22% in Q2 2021 and bottomed at 81.99% in Q1 2025.
  • The 5-year median for Operating Margin is 14.09% (2023), against an average of 16.28%.
  • The largest annual shift saw Operating Margin soared 1672bps in 2021 before it plummeted -6253bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 12.7% in 2021, then decreased by -19bps to 10.28% in 2022, then plummeted by -252bps to 15.67% in 2023, then fell by -23bps to 19.33% in 2024, then tumbled by -265bps to 70.53% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Operating Margin are 70.53% (Q4 2025), 55.61% (Q3 2025), and 73.21% (Q2 2025).